AI assistant
Sending…
HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021
Jan 15, 2021
33572_dirs_2021-01-15_5d34da10-d253-4295-81de-03b56fbf22c7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-01-13
Reporting Person: Peraza Lisa (VP, Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-13 | Common Stock | M | 552 | — | Acquired | 11811 | Direct |
| 2021-01-13 | Common Stock | F | 227 | $18.16 | Disposed | 11584 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-13 | Restricted Stock Units | $ | M | 552 | Disposed | Common Stock (552) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F3: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).
More from HERON THERAPEUTICS, INC. /DE/
Major Shareholding Notification
2026
May 13
Interim / Quarterly Report
2026
May 11
Regulatory Filings
2026
May 11
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Regulatory Filings
2026
Apr 20
Regulatory Filings
2026
Apr 6
Major Shareholding Notification
2026
Mar 27
Annual Report
2026
Feb 26